FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170804912> ?p ?o ?g. }

• W2170804912 endingPage "1614" @default.
• W2170804912 startingPage "1603" @default.
• W2170804912 abstract "Hypersensitivity reactions consist of a variable group of clinical findings and have been described for a wide variety of chemical compounds.This review characterizes the clinical profile of hypersensitivity to the nucleoside reverse transcriptase inhibitor abacavir sulfate.We performed a retrospective medical review of pooled adverse events data from approximately 200,000 patients who received abacavir in clinical trials, through expanded-access programs, or by prescription from 1996 through 2000. Screened cases of hypersensitivity were classified as either definitive or probable. Definitive cases were identified when initial symptoms resolved on interruption of abacavir therapy and returned on reintroduction of abacavir therapy.A total of 1803 cases were identified, 1302 in the 30,595 patients participating in clinical trials or the expanded-access program and 501 in patients from the post-marketing experience. On review, 176 (9.8%) of these cases were considered definitive and the remainder probable. Based on the 1302 cases identified in clinical trials or the expanded-access program, the calculated incidence of hypersensitivity was 4.3%. Symptoms reported in > or = 20% of cases of this multiorgan reaction included fever, rash, malaise/fatigue, and gastrointestinal symptoms such as nausea, vomiting, and diarrhea, among others. Respiratory symptoms occurred in 30% of cases and included dyspnea (12%), cough (10%), and pharyngitis (6%). In 90% of cases, hypersensitivity reactions occurred within the first 6 weeks after initiation of abacavir (median time, 11 days); after an initial reaction, rechallenge with abacavir resulted in the reappearance of symptoms within hours of reexposure. Hypotension was present in 25% of these rechallenge reactions. Among patients who received abacavir in clinical trials, the mortality rate was 0.03% (3 per 10,000 patients).Hypersensitivity to abacavir is an idiosyncratic reaction and a distinct clinical syndrome characterized predominantly by systemic involvement. It can be expected to appear as a treatment-limiting event in approximately 5% of patients. The appearance of clinical symptoms consistent with this syndrome mandates immediate discontinuation of abacavir. Hypersensitivity to abacavir is an absolute contraindication to subsequent treatment with any formulation that includes this agent." @default.
• W2170804912 created "2016-06-24" @default.
• W2170804912 creator A5014000664 @default.
• W2170804912 creator A5035268120 @default.
• W2170804912 creator A5052775622 @default.
• W2170804912 creator A5057176214 @default.
• W2170804912 creator A5059314318 @default.
• W2170804912 creator A5061841010 @default.
• W2170804912 creator A5072027358 @default.
• W2170804912 creator A5085142733 @default.
• W2170804912 creator A5091035436 @default.
• W2170804912 date "2001-10-01" @default.
• W2170804912 modified "2023-10-18" @default.
• W2170804912 title "Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir" @default.
• W2170804912 cites W1834076226 @default.
• W2170804912 cites W1969618788 @default.
• W2170804912 cites W1993086185 @default.
• W2170804912 cites W2008175048 @default.
• W2170804912 cites W2021918026 @default.
• W2170804912 cites W2023754591 @default.
• W2170804912 cites W2025113832 @default.
• W2170804912 cites W2032451005 @default.
• W2170804912 cites W2036752080 @default.
• W2170804912 cites W2045444507 @default.
• W2170804912 cites W2047166639 @default.
• W2170804912 cites W2075208354 @default.
• W2170804912 cites W2076661568 @default.
• W2170804912 cites W2099214387 @default.
• W2170804912 cites W2120615742 @default.
• W2170804912 cites W2129710521 @default.
• W2170804912 cites W2132767567 @default.
• W2170804912 cites W2146431647 @default.
• W2170804912 cites W2165253161 @default.
• W2170804912 cites W2168871876 @default.
• W2170804912 cites W2315214054 @default.
• W2170804912 cites W2317624504 @default.
• W2170804912 cites W2329100179 @default.
• W2170804912 cites W2331028753 @default.
• W2170804912 cites W28488281 @default.
• W2170804912 cites W4230344431 @default.
• W2170804912 cites W4235030794 @default.
• W2170804912 cites W4255344524 @default.
• W2170804912 doi "https://doi.org/10.1016/s0149-2918(01)80132-6" @default.
• W2170804912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11726000" @default.
• W2170804912 hasPublicationYear "2001" @default.
• W2170804912 type Work @default.
• W2170804912 sameAs 2170804912 @default.
• W2170804912 citedByCount "381" @default.
• W2170804912 countsByYear W21708049122012 @default.
• W2170804912 countsByYear W21708049122013 @default.
• W2170804912 countsByYear W21708049122014 @default.
• W2170804912 countsByYear W21708049122015 @default.
• W2170804912 countsByYear W21708049122016 @default.
• W2170804912 countsByYear W21708049122017 @default.
• W2170804912 countsByYear W21708049122018 @default.
• W2170804912 countsByYear W21708049122019 @default.
• W2170804912 countsByYear W21708049122020 @default.
• W2170804912 countsByYear W21708049122021 @default.
• W2170804912 countsByYear W21708049122022 @default.
• W2170804912 countsByYear W21708049122023 @default.
• W2170804912 crossrefType "journal-article" @default.
• W2170804912 hasAuthorship W2170804912A5014000664 @default.
• W2170804912 hasAuthorship W2170804912A5035268120 @default.
• W2170804912 hasAuthorship W2170804912A5052775622 @default.
• W2170804912 hasAuthorship W2170804912A5057176214 @default.
• W2170804912 hasAuthorship W2170804912A5059314318 @default.
• W2170804912 hasAuthorship W2170804912A5061841010 @default.
• W2170804912 hasAuthorship W2170804912A5072027358 @default.
• W2170804912 hasAuthorship W2170804912A5085142733 @default.
• W2170804912 hasAuthorship W2170804912A5091035436 @default.
• W2170804912 hasConcept C120665830 @default.
• W2170804912 hasConcept C121332964 @default.
• W2170804912 hasConcept C126322002 @default.
• W2170804912 hasConcept C141071460 @default.
• W2170804912 hasConcept C16005928 @default.
• W2170804912 hasConcept C197934379 @default.
• W2170804912 hasConcept C203014093 @default.
• W2170804912 hasConcept C2522874641 @default.
• W2170804912 hasConcept C2775832928 @default.
• W2170804912 hasConcept C2776452011 @default.
• W2170804912 hasConcept C2777351918 @default.
• W2170804912 hasConcept C2777447569 @default.
• W2170804912 hasConcept C2777869810 @default.
• W2170804912 hasConcept C2778570526 @default.
• W2170804912 hasConcept C2779277585 @default.
• W2170804912 hasConcept C2779465607 @default.
• W2170804912 hasConcept C2779802037 @default.
• W2170804912 hasConcept C2780216070 @default.
• W2170804912 hasConcept C2780593183 @default.
• W2170804912 hasConcept C2780727368 @default.
• W2170804912 hasConcept C61511704 @default.
• W2170804912 hasConcept C71924100 @default.
• W2170804912 hasConceptScore W2170804912C120665830 @default.
• W2170804912 hasConceptScore W2170804912C121332964 @default.
• W2170804912 hasConceptScore W2170804912C126322002 @default.
• W2170804912 hasConceptScore W2170804912C141071460 @default.
• W2170804912 hasConceptScore W2170804912C16005928 @default.
• W2170804912 hasConceptScore W2170804912C197934379 @default.

• next